Plasma p-tau217 as a two-cutoff approach to improve tau-PET screening and trial recruitment in Alzheimer’s disease
A study suggests that plasma p-tau217 is an effective blood-based biomarker for screening Alzheimer's disease and predicting tau-PET positivity. A two-cutoff diagnostic strategy helps reduce indeterminate results, potentially streamlining clinical trial recruitment.
Why it matters
Blood-based diagnostics are significantly cheaper and less invasive than PET scans, potentially democratizing early Alzheimer's detection.
Scientific Reports ( 2026 ) Cite this article
We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in